News

Home/News
News 2017-06-21T13:15:59+00:00
September 26, 2017
Catalyst Biosciences Granted FDA Orphan Drug Designation for Subcutaneous Recombinant Human Factor IX Variant for Treatment of Hemophilia B
SOUTH SAN FRANCISCO, Calif., Sept. 26, 2017 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (CBIO) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug ...
September 26, 2017
EMA’s Paediatric Committee Agrees to Albireo’s A4250 Pediatric Investigation Plan
BOSTON, Sept. 26, 2017 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced ...
September 25, 2017
Prometic receives FDA clearance of its IND to initiate pivotal PBI-4050 Phase 2/3 trial in patients with idiopathic pulmonary fibrosis
LAVAL, QC , Sept. 25, 2017 /CNW Telbec/ - Prometic Life Sciences Inc. (PLI.TO) (PFSCF) (Prometic) today announced that its oral anti-fibrotic lead drug candidate, ...
September 25, 2017
TherapeuticsMD Announces Move to Nasdaq Global Select Market
BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (NYSE American:TXMD), an innovative women’s healthcare company, today announced that it will voluntarily move its stock exchange listing to the ...
September 25, 2017
BioTime Board of Directors Approves Distribution of AgeX Therapeutics Shares to BioTime Shareholders
ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, announced today that its Board ...
September 25, 2017
Aradigm Announces FDA Acceptance of NDA for Linhaliq with Priority Review Status
Aradigm Corporation (ARDM) (the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing with Priority Review its New Drug ...
September 25, 2017
Bioblast Announces Effectiveness of Five to One Reverse Split
TEL AVIV, Israel, Sept. 25, 2017 (GLOBE NEWSWIRE) -- Bioblast Pharma Ltd. (ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced the effectiveness of a five ...
September 25, 2017
Key Clinical Study Showing Reversal of Refractory Septic Shock in Patients Treated with CytoSorb®
MONMOUTH JUNCTION, N.J., Sept. 25, 2017 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader using CytoSorb® blood purification to treat deadly inflammation in ...
September 25, 2017
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year 2017 Results
CRANBURY, N.J., Sept. 25, 2017 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of ...
September 25, 2017
iCAD Announces Presentation of New Clinical Data on Xoft System for Treatment of Nonmelanoma Skin Cancer and Early-Stage Breast Cancer at ASTRO 2017
NASHUA, N.H. and SAN DIEGO, Sept. 25, 2017 (GLOBE NEWSWIRE) --  (Booth #3139) - iCAD, Inc. (ICAD), an industry-leading provider of advanced image analysis, workflow solutions ...
September 25, 2017
Paratek Pharmaceuticals to Present New Omadacycline Data at IDWeek 2017
BOSTON, Sept. 25, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (PRTK) announced today that new data from its omadacycline clinical and microbiology programs will be ...
September 25, 2017
Soleno Therapeutics Announces Receipt of Scientific Advice from the European Medicines Agency for DCCR in Prader-Willi Syndrome
REDWOOD CITY, Calif., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare ...
September 25, 2017
BIOPHYTIS filed IND application for approval by FDA of SARA-INT Phase 2b study of Sarconeos in Sarcopenia
PARIS, Sept. 25, 2017 (GLOBE NEWSWIRE) -- BIOPHYTIS (Euronext Growth Paris:ALBPS), a biotechnology company specializing in the development of drug candidates to treat age-related diseases, ...
September 25, 2017
Catalyst Biosciences Announces Successful Completion of First Subcutaneous Dosing Cohort in Ongoing Hemophilia B Clinical Trial
SOUTH SAN FRANCISCO, Calif., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (CBIO), today announced that its collaborator ISU Abxis has completed dosing of the first ...
September 25, 2017
Acer Therapeutics Reports Positive Results From Pivotal Clinical Trial of EDSIVO™ (celiprolol) for Treatment of Vascular Ehlers-Danlos Syndrome
CAMBRIDGE, Mass., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc., (ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for ...
September 25, 2017
AzurRx Announces Appointment of Maged Shenouda as Chief Financial Officer
NEW YORK, Sept. 25, 2017 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (AZRX) (“AzurRx” or the “Company”) a company specializing in the development of non-systemic, recombinant  ...
September 25, 2017
Gemphire to Present New COBALT-1 Clinical Data at the 2017 FH Global Summit
LIVONIA, Mich., Sept. 25, 2017 (GLOBE NEWSWIRE) --  Gemphire Therapeutics Inc. (GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, ...
September 21, 2017
Lysogene Holds First Parent Advisory Board in MPS IIIA
PARIS & CAMBRIDGE, Mass.-- (BUSINESS WIRE) -- Regulatory News: Lysogene (FR0013233475 – LYS) (LYS.PA), a leading, biopharmaceutical company pioneering gene therapy technologies to treat central nervous system ...
September 21, 2017
BioTime Co-CEO Adi Mohanty to Participate in Panel Discussion at the Cell & Gene Therapy CEO Forum
ALAMEDA, Calif.-- (BUSINESS WIRE) -- BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, today announced that Co-Chief ...
September 21, 2017
Omadacycline Receives Qualified Infectious Disease Product Designation from FDA for an Additional Indication in Uncomplicated Urinary Tract Infections
BOSTON, Sept. 21, 2017 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon ...
Page 6 of 33